



UT Southwestern Pancreas Cancer Program Webinar

March 10, 2021

UT Southwestern Medical Center – Division of Surgical Oncology, Department of Surgery

Course Director

Adam Yopp, M.D.

Chief

Division of Surgical Oncology, Department of Surgery

UT Southwestern Medical Center

Purpose and Content

UT Southwestern Medical Center's multidisciplinary pancreatic cancer program provides the most innovative pancreatic robotic surgery and medical treatments available. In this webinar, we will discuss pancreatic cancer treatment in its various stages through current case-based presentations. The latest treatment options available to patients with pancreatic cancer and information on our Multidisciplinary Pancreatic cancer program will be discussed. In addition, an opportunity for open dialogue will be available to all attendees.

Target Audience

This course is designed for providers in the specialties of Surgical Oncology, Gastroenterology and Medical Oncology

Educational Objectives

Upon completion of this activity, participants should be able to:

- Identify 2 new treatment options available for patients with local pancreatic cancer.
- Describe surgical treatment options for patients with locally advanced pancreatic cancer.
- Identify treatments available in metastatic pancreatic cancer clinical trials.

Educational Methods

This webinar will discuss the latest treatment options available through current case-based presentations.

Accreditation and Credit Designation Statements

The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas Southwestern Medical Center designates this live activity for a maximum of **1.0 AMA PRA Category 1 Credit(s)[™]**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Texas Southwestern Medical Center certifies that non-physicians will receive an attendance certificate stating that they participated in the activity that was designated for **1.0 AMA PRA Category 1 Credit(s)[™]**.

Evaluation

Online course evaluations will be available 3-5 business days after the conference. The evaluation is an important tool for assessing the effectiveness of this activity as well as for planning future activities. We value your feedback.

CME and Attendance Certificates will be available online at <http://cme.utsouthwestern.edu> after completion of the online evaluation. An account must be created at cme.utsouthwestern.edu in order to claim/view credit. Instructions are available upon request for creating this profile.

If you have any questions regarding your certificate you may direct them to: cmeregistrations@utsouthwestern.edu

DISCLOSURE OF COMMERCIAL INTEREST

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), The University of Texas Southwestern Medical Center, Office of Continuing Medical Education (UTSW CME) requires that the content of CME activities and related materials provide balance, independence, objectivity, and scientific rigor. Planning must be free of the influence or control of a commercial entity, and promote improvements or quality in healthcare. All persons in the position to control the content of an education activity are required to disclose all relevant financial relationships in any amount occurring within the past 12 months with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients.

The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. The UTSW Office of CME has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity. The intent of this policy is to identify potential conflicts of interest so participants can form their own judgments with full disclosure of the facts. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity.

Faculty Disclosures

The following faculty reported to have relevant financial relationships and/or intends to discuss the use of off-label or investigational use of products.

Speaker Name	Name of Commercial Interest	Nature of Relevant Relationship
Muhammad Shalaan Beg, M.D.	Bristol Myers Squibb, Ipsen, Genentech, Cancer Commons, Foundation Medicine, Science37	Professional Services

The following faculty and planning committee members have reported to have **no relevant financial relationships** and will not be discussing any off-label or investigational use of products:

- Adam Yopp, M.D., Chief, Division of Surgical Oncology – Course Director, Moderator
- Herbert Zeh, M.D., Chair and Professor of Surgery – Speaker
- Patricio Polanco, M.D., Associate Professor of Surgery – Speaker
- Lan Vu, M.P.A.S., PA-C, Pancreas Cancer Clinic Program Manager – Speaker

Disclosure of Unlabeled Uses

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physicians’ Desk Reference.

Disclaimer

This symposium has been planned to be well-balanced and objective in discussion of comparative treatment regimens, and the symposium format allows for the free scientific exchange of ideas. Information and opinions offered by the speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information.